The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review

Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals. Despite the fact that CDI has treatment options, recurrence is common after the treatment, recurrence will occur in approximately 20%-35% of people initially affected, with 40%-60% of these having a second re...

Descripción completa

Detalles Bibliográficos
Autores principales: Thandavaram, Abhay, Channar, Aneeta, Purohit, Ansh, Shrestha, Bijay, Patel, Deepkumar, Shah, Hriday, Hanna, Kerollos, Kaur, Harkirat, Alazzeh, Mohammad S, Mohammed, Lubna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468512/
https://www.ncbi.nlm.nih.gov/pubmed/36120235
http://dx.doi.org/10.7759/cureus.27979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468512/
https://www.ncbi.nlm.nih.gov/pubmed/36120235
http://dx.doi.org/10.7759/cureus.27979

Ejemplares similares